| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
John Henry Stevens last filed a Form 4 in September 2023, as Director at CLNN. John Henry Stevens's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Our model assigns John Henry Stevens a below-average insider score of 21/100, based on 3 past trades. Over a 12-month horizon, none of those trades were profitable, with an average 12-month return of -66.4%.
At the last filing, the largest reported position was 800,204 shares of CLNN. Net of sales, the CLNN filings show accumulation of 512,632 shares.
John Henry Stevens has 16 Form 4 filings on record from April 2021 to September 2023, all as Director at Clene (CLNN), 2021–2023.
The 19 reported transactions were 14 option or other derivative awards, 3 open-market purchases, 1 option exercise and 1 stock award.
Counted by filing, the open-market trades come to 3 purchases worth about $587K and no sales.
The largest open-market purchase was 316,455 shares of CLNN at an average $0.80 on June 26, 2023, about $253K. Twelve months later CLNN was down 55%.
Shares as reported in the last Form 4 for each company; the most recent is from September 2023. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.